|
|
| Thérapies > Etude de marché sectorielle |
| Top CNS Portfolios in 2004 - The Industry Gold Standards |
|
|
|
|
€ 1 520,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Janvier 2005 |
Taille du document : |
57 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (1) |
|
|
|
| 54 pages | Juin 2003 | Anglais
|
|
|
| Main
focus: |
aircraft,cns
|
| Research
focus: |
demand analysis,market size and estimates, |
| Geographic
focus: |
usa,mexico,united kingdom |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
MarketWatch: Cancer
28 pages | Novembre 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
170,00 €
|
| |
| |
Nutraceuticals - Targeting Consumers Aged 35+
154 pages | Septembre 2000 |
Not only does the 35+ consumer group account for a significant and growing percentage of the total population; it is also at the greatest risk of major illnesses.
Despite advances in medicine |
955,00 €
|
| |
| |
Chinese Markets for Cancer Treatment Drugs
272 pages | Septembre 2005 |
China's demand for cancer treatmen drugs has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's ec |
2 835,00 €
|
| |
| |
Pipeline Insight: Neuropathic Pain - Pipeline Drugs Fail to Nail Neuropathic Pain
183 pages | Juillet 2005 |
IntroductionThe neuropathic pain market has traditionally been a poorly defined area, with widely varying drug classes prescribed.
With many drugs now in clinical trials for key neuropathic pain su |
9 120,00 €
|
| |
| |
Top CNS Portfolios in 2004 - The Industry Gold Standards
57 pages | Janvier 2005 |
IntroductionThe market for central nervous system prescription drugs grew 21.3% to reach $62.4 billion in 2003.
The growth of this massive market is due to companies accessing previously untapped p |
1 520,00 €
|
| |
| |
US Antidepressants 2004
12 pages | Décembre 2004 |
Snapdata's US Antidepressants 2004 report provides 2003 year-end market data, with 2004 estimates and five-year forecasts.
The report gives an instant overview of the US antidepressant market, and |
240,00 €
|
| |
| |
MarketWatch: Cancer
31 pages | Janvier 2005 |
Datamonitor's Cancer MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the cancer therapeutic area.
MarketWatch features all the |
160,00 €
|
| |
| |
The Cancer Outlook 2000
128 pages | Septembre 2000 |
Driven by the cytotoxic, adjunct and innovative drug classes, the cancer market grew by 16% in 1999 to a global value of almost $19bn, and is now poised on the verge of a period of significant exp |
955,00 €
|
| |
| |
Stakeholder Insight: Breast Cancer - Changing Treatment Paradigms for Local and Locally Advanced Breast Cancer
199 pages | Avril 2005 |
IntroductionAnthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer.
In recent days, however, agents such as Sanofi-Aventis's Taxotere and Astr |
9 120,00 €
|
| |
| |
Cancer Vaccines: Measuring Market Potential
232 pages | Octobre 2004 |
This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets.
Vaccine product candidates are discussed within the co |
1 200,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Top CNS Portfolios in 2004 - The Industry Gold Standards |
|
|
Introduction
The market for central nervous system prescription drugs grew 21.3% to reach $62.4 billion in 2003. The growth of this massive market is due to companies accessing previously untapped patient groups and several advances in drug technology. Given the increasing Industry interest in a multitude of commercial opportunities, the expansion of CNS is expected to continue unabated.
Scope
Commercial performance of each key CNS drug for every analyzed company over the last two years
Analysis of company positioning in psychiatry, neurology and pain management
Analysis of each company's late stage pipeline and identification of key R&D projects
Areas for expansion, in terms of both new markets and product line extensions, are analyzed, discussed and recommended for each company
Highlights
Pfizer's CNS portfolio is the best in the Industry with a strong presence in all major areas and a promising late stage pipeline. The value of its franchise is double that of the next largest portfolio and it boasts blockbuster products in all three sectors of CNS: psychiatry, neurology, and pain.
The closest CNS portfolio to Pfizer's in terms of breadth is J&J's. The company performs well in all three sectors of CNS with blockbuster products in each; namely Risperdal (psychiatry), Duragesic (pain), and Topamax (neurology).
Co-licensing agreements are becoming standard practice for leading CNS players. Combining the broad marketing reach of a top tier company with the therapy expertise of a specialist company is becoming ever important in a tough market climate.
Reasons to Purchase
Benchmark your CNS portfolio against the current leading portfolios and understand what makes a commercially successful CNS portfolio
Identify up to date issues impacting the CNS franchises of leading players
Recognize the key drugs in each company portfolio, and which offer the best commercial opportunities
|
|
TABLE OF CONTENTS
CHAPTER 1 EXECUTIVE SUMMARY 4
Scope and coverage of the Brief 4
Key finding 4
CHAPTER 2 INTRODUCTION 7
Overview of the brief 7
CHAPTER 3 TOP CNS PORTFOLIOS 9
Pfizer 9
GlaxoSmithKline 21
Johnson & Johnson 30
Eli Lilly 40
Sanofi-Aventis 48
CHAPTER 4 APPENDIX 56
Bibliography 56
Websites 56
Disclaimer 57
|
|
|
PPLSEN
|
|
|
|
|
